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Intestinal Dysbiosis in Ankylosing Spondylitis
Mary-Ellen Costello,1 Francesco Ciccia,2 Dana Willner,3 Nicole Warrington,1 Philip C. Robinson,1
Brooke Gardiner,1 Mhairi Marshall,1 Tony J. Kenna,1 Giovanni Triolo,2 and Matthew A. Brown1
Objective. Ankylosing spondylitis (AS) is a com-
mon, highly heritable immune-mediated arthropathy
that occurs in genetically susceptible individuals ex-
posed to an unknown but likely ubiquitous environmen-
tal trigger. There is a close relationship between the gut
and spondyloarthritis, as exemplified in patients with
reactivearthritis, inwhomatypicallyself-limitingarthro-
pathy follows either a gastrointestinal or urogenital
infection. Microbial involvement in AS has been sug-
gested; however, no definitive link has been established.
The aim of this study was to determine whether the gut
in patients with AS carries a distinct microbial signa-
ture compared with that in the gut of healthy control
subjects.
Methods. Microbial profiles for terminal ileum
biopsy specimens obtained from patients with recent-
onset tumor necrosis factor antagonist–naive AS and
from healthy control subjects were generated using
culture-independent 16S ribosomal RNA gene sequenc-
ing and analysis techniques.
Results. Our results showed that the terminal
ileum microbial communities in patients with AS differ
significantly (P < 0.001) from those in healthy control
subjects, driven by a higher abundance of 5 families of
bacteria (Lachnospiraceae [P ! 0.001], Ruminococcaceae
[P ! 0.012], Rikenellaceae [P ! 0.004], Porphyromon-
adaceae [P ! 0.001], and Bacteroidaceae [P ! 0.001])
and a decrease in the abundance of 2 families of
bacteria (Veillonellaceae [P ! 0.01] and Prevotellaceae
[P ! 0.004]).
Conclusion. We show evidence for a discrete
microbial signature in the terminal ileum of patients
with AS compared with healthy control subjects. The
microbial composition was demonstrated to correlate
with disease status, and greater differences were ob-
served between disease groups than within disease
groups. These results are consistent with the hypothesis
that genes associated with AS act, at least in part,
through effects on the gut microbiome.
Intestinal microbiome dysbiosis and microbial
infections have been implicated in several immune-
mediated diseases, including multiple sclerosis, inflam-
matory bowel disease (IBD), and type 1 diabetes.
Bacterial infection in the gut and urogenital tract is
known to trigger episodes of reactive arthritis, a form of
spondyloarthropathy (SpA) belonging to a group of
related inflammatory arthropathies, of which ankylosing
spondylitis (AS) is the prototypic disease. The close
relationship between the gut and SpA is exemplified in
patients with reactive arthritis, in whom a typically
self-limiting arthropathy follows either gastrointestinal
infection with Campylobacter, Salmonella, Shigella, or
Yersinia, or urogenital infection with Chlamydia. Micro-
bial involvement in AS has been suggested; however, no
definitive link has been established (1).
Up to 70% of patients with AS have subclinical
gut inflammation, and 5–10% of these patients have
more severe intestinal inflammation that progresses to
clinically defined IBD resembling Crohn’s disease (CD)
(2). The high heritability of AS, the global disease
distribution, and the absence of outbreaks of the disease
suggest that AS is triggered by a common environmental
agent in genetically susceptible individuals (3). Multiple
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genes associated with AS also play a role in gut immu-
nity, such as genes involved in the interleukin-23 (IL-23)
pathway (4), which are important regulators of intestinal
“health.” Marked overrepresentation of genes that are
associated with CD is also associated with AS (5); this
suggests that the 2 diseases may have similar etiologic
mechanisms, possibly involving gut dysbiosis.
Several studies have shown that patients with AS
and their first-degree relatives have increased intestinal
permeability relative to unrelated healthy control sub-
jects, which, again, is consistent with a role for the gut
microbiome in AS (6). To date, no comprehensive
characterization of intestinal microbiota in patients with
AS has been performed. We therefore performed
culture-independent microbial community profiling of
terminal ileum biopsy specimens to characterize and
investigate differences in the gut microbiome between
patients with AS and healthy control subjects.
PATIENTS AND METHODS
Biopsy specimens from the terminal ileum were ob-
tained at the time of colonoscopy from 9 consecutively en-
rolled tumor necrosis factor inhibitor–naive patients with
recent-onset (duration from symptom onset !48 months) AS
(defined according to the modified New York classification
criteria for AS [7]) and 9 healthy control subjects (Table 1)
(see also Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38967/abstract). All patients gave written informed
consent, and the study protocol was approved by the relevant
University of Palermo and University of Queensland research
ethics committees. One patient with AS was receiving non-
steroidal antiinflammatory drugs (NSAIDs) at the time of
biopsy. AS patients 3, 4, and 10 had reported occasional use of
NSAIDs, which was interrupted due to gastrointestinal upset.
Other patients with AS did not report use of NSAIDs but were
receiving either acetaminophen and/or tramadol.
The terminal ileum microbial and mock communities
were profiled by high-throughput amplicon sequencing of the
16S ribosomal RNA (rRNA) gene (2! 250-bp barcode) on an
Illumina MiSeq sequencer using dual-indexed v4-region for-
ward primer 517F (5"-GCCAGCAGCCGCGGTAA-3") and
reverse primer 803R (5"-CTACCRGGGTATCTAATCC-3").
In addition to exploring community-level differences between
disease states, we evaluated technical and biologic replication.
Biologic replication was examined by halving the biopsy spec-
imens and performing all subsequent studies in parallel to
assess the reproducibility of findings from the time of biopsy
forward. Technical replication was performed by analyzing
forward and reverse sequencing reads separately and then
comparing them. The resulting sequence libraries were ana-
lyzed using the Quantitative Insights Into Microbial Ecology
(QIIME) pipeline (8).
Alpha diversity metrics, which are used to examine the
diversity within a sample, were generated using the QIIME
workflow. Hierarchical clustering was performed, using the
unweighted pair group method with arithmetic mean (includ-
ing both the weighted and unweighted UniFrac distance) to
detect significant differences within microbial communities
between patients with AS and healthy controls. The weighted
UniFrac distance metric detects changes in the number of
organisms present in a community, taking into account the
relative abundance of microbes present. The unweighted Uni-
Frac distance metric describes community membership. Uni-
Frac, enabled in QIIME, was used to generate sample distance
Table 1. Characteristics of the patients with AS and the healthy control subjects at the time of biopsy*
Subject
ID
Age,
years Sex
Disease duration,
years†
ESR,
mm/hour
CRP,
mg/liter BASDAI
HLA–B27
status
NSAID
treatment
Histologic
inflammation
AS01 56 M 7 34 18 7 Positive Current Chronic
AS02 33 M 4 22 1 5.5 Positive None Acute
AS03 24 F 5 18 5 4.8 Positive None Normal
AS04 22 M 3 33 3 5.5 Positive None Normal
AS05 33 M 5 41 2.7 6 Positive None Chronic
AS06 28 M 6 28 1.5 6.2 Positive None Normal
AS08 36 M 8 34 1.5 5.6 Positive None Acute
AS09 38 F 6 45 2.2 6.7 Positive None Chronic
AS10 31 M 11 27 1.3 8 Positive None Normal
HC01 58 F – – 0.3 – – – –
HC02 43 M – – 0.5 – – – –
HC03 38 F – – 0.05 – – – –
HC04 65 M – – 0.8 – – – –
HC05 48 F – – 0.02 – – – –
HC06 34 F – – 0.03 – – – –
HC07 45 M – – 0.5 – – – –
HC08 44 F – – 0.8 – – – –
HC09 56 F – – 0.02 – – – –
* In all subjects, the ileum was the biopsy site. AS # ankylosing spondylitis; ESR # erythrocyte sedimentation rate; CRP # C-reactive protein;
BASDAI # Bath AS Disease Activity Index; NSAID # nonsteroidal antiinflammatory drug; HC # healthy control.
† Beginning at the onset of symptoms.
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metrics as well as principal coordinate analysis (PCoA). Core
microbiome analysis as well as supervised learning were per-
formed to further characterize the intestinal microbial signa-
ture, using the workflow pipelines in QIIME (8). The function
of bacteria and communities was predicted using PICRUSt (9).
To determine differences in the microbial load, the
total microbial biomass in biopsy samples was quantified using
real-time quantitative polymerase chain reaction (PCR) ana-
lysis of the 16S rRNA gene, as described by Willner et al (10).
PERMANOVA analysis was conducted at the genus level
using the vegan package in R to test the relationship between
the whole microbial community and disease. Indicator species
analysis was performed using the labdsv package in R. Co-
occurrence network analysis was conducted using the spaa
package in R.
RESULTS
The microbial communities in the terminal ileum
of patients with AS were significantly different (Figure
1A) and more diverse (Figure 1C) compared with those
in healthy control subjects (P $ 0.001), as determined
using PERMANOVA. PCoA showed that AS samples,
including biologic replicates, grouped separately from
control samples, indicating that disease is the primary
factor influencing the community differences (Figure
1B) (see also Supplementary Figure 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38967/abstract).
To further demonstrate the distinct groupings of
AS samples and control samples, supervised learning
was conducted to test the predictive capacity of the
microbiome differences, and all 9 samples obtained from
patients with AS had been predicted to be AS samples
(Figure 1B). PERMANOVA analysis further confirmed
the presence of a significant relationship between dis-
ease status and microbial community composition (P $
0.001). This was not due to heterogeneity in biopsy
samples, because biologic replicates showed no signifi-
cant differences between each other. Quantitative PCR
analysis of biomass showed no significant differences, on
average, in the 16S rRNA copy number between AS
samples and control samples, indicating that the ob-
served differences were not attributable to overgrowth
or dominance of bacteria driving community differences
(see Supplementary Figure 2, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38967/abstract). The average UniFrac
distances demonstrated that differences between both
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Figure 1. A, Difference in taxonomy at the phylum level between patients with ankylosing spondylitis (AS) and healthy control subjects (HCs),
showing the increase in Bacteroides and the change in the Bacteroides-to-Firmicutes ratio in the AS samples. B, Distinct clustering of AS samples
compared with control samples, as determined by weighted principal coordinate analysis (PCoA). Supervised learning showed that all 9 AS samples
were predicted to be AS. C, Alpha diversity box plot showing increased microbial diversity (observed species) in AS samples compared with control
samples. Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median,
and the lines outside the boxes represent the 10th and 90th percentiles. D, Comparison of variation within and between disease status, showing
greater significance between and within disease status than between technical replicates and biologic replicates. Values are the mean % SD.
!!! # P $ 0.001 by Mann-Whitney test. NS # not significant.
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biologic and technical replicates were significantly less
than differences between individuals and disease states
(P $ 0.001, by Mann-Whitney test) (Figure 1D).
Community profiling showed 51 genera across all
biopsy specimens, with major differences observed at the
phylum level between AS and control specimens (Figure
1A). Indicator species analysis was performed to deter-
mine whether alterations in specific species were driving
the differences observed between communities in pa-
tients with AS and healthy control subjects. This analysis
showed that, compared with the microbial communities
in healthy control subjects, those in patients with AS
were characterized by a higher abundance of Lachno-
spiraceae, including Coprococcus species and Roseburia
species (P # 0.001), Ruminococcaceae (P # 0.012),
Rikenellaceae (P # 0.004), Porphyromonadaceae includ-
ing Parabacteroides species (P # 0.001), and Bacte-
roidaceae (P # 0.001). Decreases in the abundance of
Veillonellaceae (P# 0.01) and Prevotellaceae (P# 0.004)
were observed (Figure 2A).
Further drilling down into the AS microbiome
signature using co-occurrence analysis, which examines
the correlation between microbes, showed that bacterial
interactions further shape the AS microbial community
signature, with positive correlations observed between
the indicator species Lachnospiraceae and Ruminococ-
caceae and negative correlations observed between Veil-
lonella and Prevotella (Figure 2B). Microbial functional
prediction using PICRUSt indicated 31 significant path-
ways with differential representation in patients with AS
compared with healthy controls (P $ 0.02, with Bonfer-
roni correction) (see Supplementary Table 2, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38967/abstract).
These pathways included a decrease in bacterial invasion
of epithelial cells (P # 4.33 ! 10&5), an increase in
antimicrobial production in the butirosin and neomycin
biosynthesis pathway (P # 0.002), which is consistent
with an increase in bacteria from the Bacteroidaceae
family, and an increase in the secondary bile acid
biosynthesis pathway (P # 0.004), which is consistent
with an increase in Clostridia and Ruminococcaceae
species.
We were interested in further interrogating the
AS microbiome signature, which is the overall combina-
tion of microbes that distinguishes patients with AS from
healthy control subjects, by investigating whether an
assemblage or “core” set of microbes was present in all
AS and control samples at varying levels, and to probe
their functional capacity. Exploring the core microbiome
is imperative to better understand the stable and consis-
tent components across complex microbial communities,
given the distinct AS microbial signature. The Core 100
species (microbes present in all samples) included the
Clostridium, Actinomycetaceae, Bacteroidaceae, Lachno-
spiraceae, Porphyromonadaceae, Rikenellaceae, Rumino-
coccaceae, and Veillonellaceae families of bacteria. These
families of bacteria are also AS indicator species, sug-
gesting that the core microbiome is driving the AS
microbial signature (Figure 2A).
The Core 100 species belonged to 22 significant
pathways (P $ 0.02, with Bonferroni correction) (see
Supplementary Table 3, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38967/abstract) that again included bac-
terial invasion of epithelial cells (P # 0.004), antimicro-
Figure 2. A, Differences in the abundance of bacterial families be-
tween patients with ankylosing spondylitis (AS) and healthy control
subjects. The first 7 families of bacteria (from left to right) are AS
indicator species, and the last 3 bacterial families are control indicator
species. B, Co-occurrence network showing positive (blue lines) and
negative (red lines) correlations between AS indicator species includ-
ing members of the Lachnospiraceae family (Coprococcus and Rose-
buria); Parabacteroides, which is a member of Porphyromonadaceae;
and Faecalibacterium, which is a member of the Ruminococcaceae
family. Increasing thickness of the lines indicates increasing strength of
(Pearson’s) correlation.
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bial production in the butirosin and neomycin
biosynthesis pathway (P# 0.007), and the secondary bile
acid biosynthesis pathway (P # 0.013). Members of the
Bacteroides, Clostridium, and Ruminococcus groups are
known to be involved in cholesterol metabolism and
secondary bile synthesis; disordered bile acid synthesis
due to intestinal dysbiosis has previously been impli-
cated in the pathogenesis of IBD (11).
As the threshold for core membership was re-
duced to 90%, 75%, and 50%, the families of bacteria
present remained the same; however, the number of
genus and species within these families increased, espe-
cially in Clostridia, Lachnospiraceae, and Ruminococcus.
This demonstrates that the structure of the core micro-
biome is robust, and that decreasing the threshold
expands the number of genera and species of bacteria
only within these families. As the core threshold de-
creased, however, the number of significant pathways
also decreased, suggesting that as the threshold is re-
laxed, the expansion of genera and operational taxo-
nomic units dilutes pathway signals.
Indicator species analysis also determined that
healthy control subjects had an increased abundance of
Streptococcus and Actinomyces compared with patients
with AS. No difference was noted between patients with
AS and control subjects in the presence of either bacte-
ria known to be associated with reactive arthritis or
Klebsiella species, which have been proposed to play a
role in triggering AS (12).
DISCUSSION
Here, we present the first characterization and
identification of intestinal dysbiosis in the AS micro-
biome, using 16S rRNA community profiling of terminal
ileum biopsy specimens. We show evidence for a discrete
microbial signature in the terminal ileum of patients
with AS compared with healthy control subjects. The
microbial profile differences are not attributable to
differences in overall bacterial quantity between patients
with different diseases but are qualitative. PCoA was
able to show the distinct grouping of patients with AS
versus healthy control subjects; larger studies will be
required to define the individual bacterial species in-
volved. Statistically, the relationship between disease
status and microbial community composition was con-
firmed, indicating that the differences in composition of
the microbial community were not due to heterogeneity
in the biopsy specimens or a lack of technical reproduc-
ibility, but that the driving force is disease state.
Of the 7 families of microbes with differences in
abundance within the AS microbiome, Lachnospiraceae,
Ruminococcaceae, and Prevotellaceae are strongly asso-
ciated with colitis and CD, with Prevotellaceae especially
known to elicit a strong inflammatory response in the
gut (13). Further investigations showed that correlations
between these families of bacteria further shape the AS
microbial signature, and that these microbes were pres-
ent in all AS samples studied, suggesting that they are
not only driving the microbial signature but also are at
the core of the AS microbial signature. Increases in
Prevotellaceae and decreases in Rikenellaceae in the
intestinal microbiome have also recently been observed
in the HLA–B27–transgenic rat model of spondylo-
arthritis, suggesting that underlying host genetics may
play a role in sculpting the gut microbiome in this animal
model (14).
The increased diversity of the AS community
without an overall change in microbial load shows that
no overgrowth or dominance of a particular microbe
drives the signature. However, murine experiments dem-
onstrate that both the overall composition of the intes-
tinal microbiome and the presences and/or absence of
specific microbes can have a substantial impact on host
response, regulation of inflammation, and development
of intestinal cells. In the K/BxN mouse model of arthri-
tis, it was shown that the introduction of a single
gut-residing species, segmented filamentous bacteria,
into germ-free mice was sufficient to reinstate Th17
cells, leading to the production of autoantibodies and
arthritis. When IL-17 was neutralized in specific
pathogen–free K/BxN mice, development of arthritis
was prevented. Thus, a single commensal microbe, via its
ability to promote a specific T helper cell subset, can
drive immune-mediated disease (15).
Further studies are needed to investigate whether
the changes in intestinal microbial composition are due
to host genetics and how this affects the overall function
of the gut microbiome in AS patients, including how the
microbiome then goes on to shape the immune response
and influence inflammation. In particular, given the
strong association of HLA–B27 with AS, it has been
hypothesized that HLA–B27 induces AS by effects on
the gut microbiome, in turn driving spondyloarthritis-
inducing immunologic processes such as IL-23 produc-
tion (16). Our data showing intestinal dysbiosis in pa-
tients with AS is consistent with this hypothesis, but
further studies are clearly required to distinguish cause-
and-effect interactions between the host genome and
immune system and the gut microbiome. These investi-
gations will provide new insights and help us to better
understand the pathogenesis of AS.
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